Elan (6099.T) Osake Kurssi
Elan Kurssi
Viimeisten 13 vuoden aikana Elann liikevaihto kasvoi 21,1 % vuodessa ja ylsi 55,45 Mrd. JPY:een. Osakekohtainen tulos on kasvanut 14,7 % vuodessa viimeisten 13 vuoden aikana. Elann nettomarginaali 5,0 % on laskenut verrattuna 6,0 %:iin muutama vuosi sitten. Nykyhinnalla osinkotuotto on noin 2,15 %. Jakosuhde on noin 33 % tuloksesta. Osinko on kasvanut 42,2 % vuodessa viimeisten 11 vuoden aikana. Elann 12 kuukauden konsensustavoitehinta on 1 020,00 JPY, noin yli kurssia 46,3 %. 6 analyytikosta 4 suosittaa ostoa — kokonaiskonsensus on Osta.
Elan osakekurssi
Elan liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Elan -osakkeesta
Elan Corp, a leading pharmaceutical company, has a strong business model focused on developing and commercializing innovative therapies. With a primary focus on neurological disorders, Elan Corp strives to improve patients' lives by researching and delivering effective treatments. They collaborate with top scientists, physicians, and industry partners to identify and develop promising drug candidates. Through strategic investments and partnerships, Elan Corp aims to accelerate the development process and ensure effective distribution of its products worldwide. By combining scientific excellence, market insights, and a patient-centric approach, Elan Corp remains committed to transforming healthcare and providing valuable solutions for individuals battling neurological disorders.
Elan Corp is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Elan Corp in the market include Biogen Inc., Novartis AG, Takeda Pharmaceutical Company Limited, and Amgen Inc.
Elan Corp is a renowned pharmaceutical company with a rich history and background. Established in 1969, it has grown into a global player in the biotechnology industry. Elan Corp focuses on developing innovative therapies for various medical conditions, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Over the years, the company has gained recognition for its cutting-edge research and development initiatives. With a strong commitment to improving patient outcomes, Elan Corp has built a reputation for delivering high-quality products that address critical unmet medical needs. Today, it continues to prioritize advancements in healthcare through its dedicated team of scientists, researchers, and healthcare professionals.
Elan Corp, a leading pharmaceutical company, has achieved numerous significant milestones. One of the notable achievements includes the development and launch of Tysabri, a breakthrough treatment for multiple sclerosis. Another milestone is the successful collaboration with Biogen on Tysabri, which showcased the company's strong expertise in partnerships. Elan Corp has also embarked on several successful acquisitions, such as its merger with Perrigo in 2013, expanding its portfolio and global reach. Moreover, the company's dedication to innovation is evident through continuous research and development efforts, leading to the advancement of novel therapies in various therapeutic areas.
Elan Corp is primarily present in multiple countries and regions worldwide. With a global presence, the company operates in various key markets, including the United States, Ireland, and other parts of Europe. Additionally, Elan Corp has established a prominent presence in emerging markets such as Asia and Latin America, further expanding its reach and potential for growth. By strategically expanding their operations across different geographies, Elan Corp aims to tap into diverse markets and leverage regional opportunities to drive success and enhance shareholder value.
Elan Corp represents values of innovation, collaboration, and patient-centered focus. The company's corporate philosophy emphasizes the development of groundbreaking therapies and solutions to improve the lives of patients worldwide. With an extensive portfolio of research and development, Elan Corp aims to lead the way in healthcare advancements, ensuring excellence in quality, safety, and efficacy of its products. By leveraging its expertise and strategic partnerships, Elan Corp strives to make a positive impact on the healthcare industry and contribute to the betterment of society.
Analyytikot asettavat tällä hetkellä Elan-osakkeelle keskimääräisen tavoitehinnan 1 020,00 JPY (mediaani: 1 020,00 JPY), mikä merkitsee +46,3 % viimeisimpään hintaan verrattuna. Konsensus perustuu 6 analyytikkoarvioon.
7 analyytikkoa arvioi tällä hetkellä Elan-osaketta: 0 suosittaa ostoa, 3 pitoa ja 4 myyntiä. Vuodelle 2026 analyytikot odottavat Elan-yhtiöltä 61,00 Mrd. JPY liikevaihtoa ja 52,90 JPY osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Elan-osake noteerataan hintaan 3,94 EUR (697,00 JPY).
Elan-osake (6099.T) on listattuna 2 pörssissä, muun muassa: Tokio (JPX) (6099.T), Frankfurt (25E.F).
Elan Corp is an Irish pharmaceutical company that focuses on the development, manufacturing, and marketing of specialized medicines. It serves both the US and European markets with a focus on unmet medical needs and innovative technologies. The article describes Elan's business model, key business areas, and products as well as its market orientation. Elan Corp's business model encompasses the entire value chain from research and development to production and sales of pharmaceutical products. The company focuses on developing and licensing innovative technologies in the medical industry and has a coordinated and differentiated product portfolio. Elan Corp operates three business areas: biopharmaceuticals, product innovations, and Elan Drug Technologies (EDT). The biopharmaceuticals division specializes in developing drugs for neurodegenerative diseases such as Alzheimer's, Parkinson's, and multiple sclerosis, with Tysabri being a well-known product in this area. The product innovations division conducts an intensive research and development program aimed at discovering and launching new products. The EDT division offers a variety of patented and innovative technologies for improving drug delivery and absorption. Elan offers a wide portfolio of medications for the treatment of neurodegenerative diseases, autoimmune diseases, and cancer. The company provides various products and technologies, including proprietary technologies for enhancing drug efficacy and reducing adverse effects, for the therapy of various diseases and medical conditions. Elan Corp specializes in the development of Tysabri, a medication for the treatment of multiple sclerosis. It is a monoclonal antibody drug administered as an infusion that slows disease progression and reduces the frequency of relapses. Elan Corp is an internationally operating company specializing in the US and European markets. It particularly relies on targeted local marketing and sales strategies to expand its customer base and provide comprehensive product information. In summary, Elan Corp focuses on the development and marketing of medications for the treatment of neurodegenerative diseases, cancer, and autoimmune diseases. The company operates a coordinated portfolio and utilizes patented technologies to improve drug efficacy and reduce adverse effects. Elan has particularly focused on the US and Europe and is known in the industry as an innovative, future-oriented provider.
odotettu liikevaihto Elan on 61,00 Mrd. JPY. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Elan on 3,20 Mrd. JPY. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Elan:n hinta-voitto-suhde (P/E) on tällä hetkellä 13,18. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Elan-osakkeen arvostusta.
Elan:n hinta-myynti-suhde (P/S) on tällä hetkellä 0,69. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Elan-osakkeen arvostuskennuslukuna.
Elan:n Eulpool-laatuscore on 8/10.
Elan:n ISIN on JP3167680002. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Elan:n WKN on A12C13. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Elan:n ticker on 6099.T. Tämä pörssinoteeraus käytetään Elan-osakkeiden kauppaan pörssissä.
Elan osake
Elan vertaisryhmä
Elan Ticker
Elan FIGI
Kaikki tunnusluvut ja syvällinen analyysi Elan:sta
Meidän osakeanalyysimme Elan-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Elan:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: